糖尿病中的GLP-1R:从基本发现到治疗开发
Shujun Li1, Nanqu Huang2,3, Mei Wang4
1Key Laboratory of Basic Pharmacology and Joint International Research Laboratory of Ethnomedicine of Ministry of Education, Zunyi Medical University, Zunyi, Guizhou, China.
Frontiers in pharmacology
|June 16, 2025
概括
葡萄糖类-1受体 (GLP-1R) 是治疗糖尿病的关键标. GLP-1R激动剂在控制血糖和相关并发症方面表现有前途.
科学领域:
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 糖尿病 (DM) 是一种全球性健康挑战,其特点是高血糖.
- 葡萄糖类-1受体 (GLP-1R) 是一种与G蛋白结合的受体,对葡萄糖平衡至关重要.
- GLP-1R在各种组织中表达,包括胰岛岛,中枢神经系统和肠道.
研究的目的:
- 审查GLP-1R的结构和功能特性.
- 探索GLP-1R在葡萄糖平衡中的作用及其在糖尿病中的治疗应用.
- 总结GLP-1R激动剂的临床进展情况.
主要方法:
- 关于GLP-1R结构,功能和临床应用的文献综述.
- 对胰腺小岛,中枢神经系统和肠道中的GLP-1R机制的分析.
- 对GLP-1R激动剂的疗效和安全性临床数据的评估.
主要成果:
- 激活GLP-1R可增强胰岛素分泌并抑制葡萄糖分泌.
- GLP-1R在β细胞保护,延迟胃空化和腹感方面发挥作用.
- GLP-1R激动剂在糖尿病治疗中显示出临床疗效和安全性.
结论:
- GLP-1R是糖尿病的重要治疗点.
- GLP-1R激动剂为治疗糖尿病及其并发症提供了一个有希望的方法.
- 对GLP-1R通路的进一步研究可能会产生新的治疗策略.
相关概念视频
Glucagon-like Receptor Agonists
438
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
438
Oral Hypoglycemic Agents: Glinides
274
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
274
Dipeptidyl Peptidase 4 Inhibitors
271
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
271
Insulin: Biosynthesis, Chemistry, and Preparation
570
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
570
Insulin: The Receptor and Signaling Pathways
1.5K
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
1.5K
Oral Hypoglycemic Agents: Biguanides and Glitazones
310
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
310


